Evaluating mitochondrial DNA in patients with breast cancer and benign breast disease

J Cancer Res Clin Oncol. 2011 Apr;137(4):669-75. doi: 10.1007/s00432-010-0912-x. Epub 2010 Jun 16.

Abstract

Purpose: To evaluate the role of mtDNA in breast cancer.

Methods: We carried out an investigation into the mtDNA major control region or D-loop region and an essential and the largest mtDNA protein-coding gene, NADH dehydrogenase subunit 5 (ND5), together with a mitochondrial haplogroup analysis in 64 patients with breast cancer (BC) and 54 patients with benign breast disease (BBD) as controls.

Results: Mutations in D-loop region were found in 10/64 or 15.6% of patients with BC and 14/54 or 25.9% of patients with BBD, while mutations in ND5 were detected in 6/64 or 9.4% of patients with BC and 5/54 or 9.3% of patients with BBD. In addition, in patients with BBD, mtDNA mutations were more likely to rise in D-loop region and the mutations were more likely to be heteroplasmic. However, in patients with BC, those with metastatic feature were less likely to carry mutations in D-loop region. Finally, we found haplogroup M has an increased risk of breast cancer compared with haplogroup N.

Conclusion: mtDNA mutation may play a role in early stage of tumorigenesis, and mitochondrial haplogroup can also modulate breast cancer occurrence.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Breast Diseases / genetics*
  • Breast Neoplasms / etiology
  • Breast Neoplasms / genetics*
  • DNA, Mitochondrial / genetics*
  • Electron Transport Complex I / genetics
  • Female
  • Haplotypes
  • Humans
  • Middle Aged
  • Mitochondrial Proteins / genetics
  • Mutation

Substances

  • DNA, Mitochondrial
  • Mitochondrial Proteins
  • MT-ND5 protein, human
  • Electron Transport Complex I